Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies. - Wikidata - awgldk - TriplyDB

Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

http://www.wikidata.org/entity/Q38079317

about

Biomarkers of Parkinson's disease: present and future Emerging preclinical pharmacological targets for Parkinson's disease Neuroinflammation in Multiple System Atrophy: Response to and Cause of α-Synuclein Aggregation Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation Disease-modifying therapeutic directions for Lewy-Body dementias Alpha-synuclein biology in Lewy body diseases Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo.The Cleavage Effect of Mesenchymal Stem Cell and Its Derived Matrix Metalloproteinase-2 on Extracellular α-Synuclein Aggregates in Parkinsonian Models Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.A generic method for design of oligomer-specific antibodies.Chaperoned amyloid proteins for immune manipulation: α-Synuclein/Hsp70 shifts immunity toward a modulatory phenotype Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Combination therapies: The next logical Step for the treatment of synucleinopathies?Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy Application of amide hydrogen/deuterium exchange mass spectrometry for epitope mapping in human cystatin C.Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.Developing therapeutic antibodies for neurodegenerative disease.Tau immunotherapy and imaging.Genetics and genomics of Parkinson's disease.Therapeutic strategies in Parkinson's disease: what we have learned from animal models.Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.Active immunization therapies for Parkinson's disease and multiple system atrophy.Therapeutic approaches in Parkinson's disease and related disorders.Immunotherapies for neurodegenerative diseases: current status and potential of plant-made biopharmaceuticals.Recombinant Antibody Fragments for Neurodegenerative Diseases.Targets and Mechanisms in Prevention of Parkinson's Disease through Immunomodulatory Treatments.Implications of peptide assemblies in amyloid diseases.A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies.α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease.Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.Impact of subunit linkages in an engineered homodimeric binding protein to α-synuclein.Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments.

P2860

Q24170134-90780BED-AC74-41A3-8C94-A53D53B7AD36 Q26764724-2D858337-4F4F-4721-8D60-50D5A2640D60 Q26771536-E5EFA516-9136-48BF-82BB-F48BFDF2FF59 Q26781130-658E0B10-7187-41D6-9FB4-8D374F242E66 Q26782907-1D96488B-4040-4327-8F2D-0B4600F4EBD4 Q27003541-8F13CD5B-C80B-4B8A-B712-F85B281B72F0 Q27015811-1C4E9756-F548-4DE5-AE25-6C12959124C7 Q27686837-C5DC7621-DC56-4DFC-9F84-72C18A059443 Q30578913-73E35FA4-DDAC-471B-999A-3925C765CB6A Q30650119-85F35A81-525C-4FCB-A4F7-8B083FF56D52 Q33722313-8E789CB0-FF6D-47B9-A8D0-011DFF6E7B6D Q33865366-2154CB66-C60A-4250-9254-B6E96C869924 Q35058359-C9411D83-2331-446B-828C-51A7C1C06553 Q35117526-A9CB0B68-BDC3-4B09-8FF7-B4568201F811 Q35285839-42BA27D0-EFC7-4DB3-A400-CD1FBDF73877 Q35544737-7086F50F-6B94-4861-8FE6-78ABD11443C2 Q35854093-E38554D6-6694-4998-AABB-3D20D532D168 Q36484413-CE39BF00-0C38-4434-8C73-8207C478C478 Q36563062-D07FB60E-32DC-45C0-9C48-2A6A6CD05447 Q36672116-92AE7311-50B9-44F8-98EA-73535F028538 Q37198050-75F996B0-59C8-4357-970E-33DFC9398826 Q37280507-9E05BB1F-9FCE-48DF-8D75-F0E71BEA01DB Q37410752-37A81CEC-BEC4-4704-B4AB-F30BB31A6462 Q37586721-3919390E-8D3F-419D-BA00-AC538AE6CFEF Q38095360-08EB7B38-7E5D-40A7-A441-A31DD066A000 Q38136880-A6AAE3A2-E7EC-451E-BAA7-AE0B86ED97B8 Q38233866-3148A3DC-0C8D-4F61-BEEE-755B4858E34B Q38290759-172F3E0C-363F-4B38-A62C-D384030EDA2B Q38541943-55B7453B-AF20-4375-A0A6-9D50D5437CE8 Q38564102-A18FA4E7-6216-4E69-A9C6-1CD8E0EF54C0 Q38691406-C0928AA0-3423-4D48-BF76-3662FE3B519E Q38942195-0DC95053-DADD-4539-A5D6-1E185B4CA133 Q38970823-3C8B937D-0F96-4965-BA99-5A5D5AE8A8F4 Q39148230-CC7B78E8-EEA5-4BAD-9679-868D5DA23BC1 Q39431937-1C5714CD-0D84-4D09-A4AE-338570A7AA71 Q41069719-1A888609-A691-43EF-A182-827722DFC723 Q41117719-4A551AC9-1710-4E38-B5A1-D0133230B3E2 Q42095746-B12CCDD9-8D52-43F5-BBE2-89934A216A34 Q44675901-AA5FFCF8-3E41-43D8-BEC9-F09433D787D9 Q45873810-1EC25D59-E98C-400A-921F-DBF7583EAABC

P2860

Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

http://www.wikidata.org/entity/Q38079317

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

@en

type

label

Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

@en

prefLabel

Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

@en

P1433

Q38079317-B8193AAE-601E-472C-AF9B-9C551E044293

P1476

Q38079317-27F89B2B-27B5-4A3E-A416-723E10935800

P2093

Q38079317-5D727E23-9CC4-42F2-9DA1-79A7334ED863

P2860

Q38079317-0007D52B-43FF-4CDA-89BE-BFBEFB553D81

Q38079317-029B89A3-A24B-4216-88DC-1BF15AD7EF6C

Q38079317-0417E37B-BC58-4C0F-A3DB-2E1A2459CD79

Q38079317-06F657D7-63FD-401E-8D61-85FC622B2FB0

Q38079317-07D1242E-8913-404B-A435-1FE82040FD19

Q38079317-09C64F40-5ED7-4305-A73F-FDA32D1EA474

Q38079317-09CD0BDB-17A5-4107-BB9B-286D602F0E8C

Q38079317-0B3AF62B-C239-4BBA-BAB4-36FFB5549170

Q38079317-0CFEC0E4-5A16-499A-819D-43C0DEB45D10

Q38079317-0DB77A9A-6E04-46FE-A5D5-BC8C7EFC46D6

P304

Q38079317-990B1779-6134-421A-A5B1-332DC418BFE4

P31

Q38079317-BDA03C93-97EB-4E51-85AE-3E4F08DF65E4

P356

Q38079317-2716DB6B-1378-42A3-9983-79AAEC9AA5B9

P433

Q38079317-8B536EBE-D868-4F3D-9A9C-FF03B2117C10

P478

Q38079317-34193496-8B21-4B42-AA18-8046D3A2D694

P50

Q38079317-C18FE472-2317-4303-8B85-0EB74CEDDDB1

P577

Q38079317-99A6A656-4834-49A0-BA1F-61A299536A78

P5875

Q38079317-80CDDBD7-25CF-4C82-980C-9571147A92BC

P698

Q38079317-A9F93846-59F4-4058-9E58-2896832EB23B

P921

Q38079317-112C3B76-5E22-4DB7-88EA-B3E8E79ED637

Q38079317-DC956D71-3B00-465D-A4B2-1A8B8138C250

P932

Q38079317-5ECFC556-D572-4815-9693-EA4FEBFAFA7F

P356

J.PHARMTHERA.2013.01.013

P1433

Pharmacology & Therapeutics

P1476

Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

@en

P2093

Elvira Valera

http://www.w3.org/2001/XMLSchema#string

P2860

The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies

Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease

Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36.

A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease

α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells.

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease

Second consensus statement on the diagnosis of multiple system atrophy

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein

Microglia and neuroinflammation: a pathological perspective

P304

311-322

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PHARMTHERA.2013.01.013

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

138

http://www.w3.org/2001/XMLSchema#string

P50

Eliezer Masliah

P577

2013-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235404486

http://www.w3.org/2001/XMLSchema#string

P698

23384597

http://www.w3.org/2001/XMLSchema#string

P921

neurodegeneration

P932

3925783

http://www.w3.org/2001/XMLSchema#string